The Latest Analyst Ratings for CRISPR Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 13 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. The average price target for the stock is $68.46, with a high of $88.00 and a low of $42.00. The average price target has increased by 8.67% over the past month.
July 25, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have a mixed view on CRISPR Therapeutics with an average price target of $68.46. The target has increased by 8.67% over the past month.
The mixed analyst ratings indicate uncertainty about the stock's future performance. However, the increase in the average price target over the past month suggests a positive trend.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100